Rx License-Rx

TAB-2822

Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources

CDC researchers have developed a bead-based nucleic acid assay for serotyping members of the Salmonella genus; this assay will identify serotypes for approximately 95% of all human-obtained Salmonella isolates in the United States. Presently, production and quality control for the more than 250 antisera required to cover the >2,500 known serotypes using current methods is difficult, expensive and laborious. Many clinical Salmonella isolates can require three to five days to determine serotype, delaying conclusive serotype identification and postponing alerts to public health monitoring programs. To that end, this new assay provides improved diagnostic identification and discrimination as well as reducing reagent consumption and technician labor. The assay has been developed and optimized in parallel with traditional serotyping methods on a panel of 368 isolates that represents all subspecies/serogroup combinations in the current...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Infectious Disease

Indication: Infectious Disease

Modality: Diagnostic / Biomarker

Focus tags: Infectious Disease

Technology tags: Diagnostic / Biomarker, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: Issued; Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Infectious Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Infectious Disease. Public description: CDC researchers have developed a bead-based nucleic acid assay for serotyping members of the Salmonella genus; this assay will identify serotypes for approximately 95% of all human-obtained Salmonella isolates in the United States.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Infectious Disease

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.